Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 52, 2017 - Issue 2
Submit an article Journal homepage
1,559
Views
19
CrossRef citations to date
0
Altmetric
Original Article

Analysis of the cost-effectiveness of using vonoprazan–amoxicillin–clarithromycin triple therapy for first-line Helicobacter pylori eradication

Yusaku KajiharaDepartment of Gastroenterology, Fuyoukai Murakami Hospital, Aomori, Japan; Correspondence[email protected]
,
Tadashi ShimoyamaDepartment of Gastroenterology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
&
Ichiro MizukiDepartment of Gastroenterology, Fuyoukai Murakami Hospital, Aomori, Japan;
Pages 238-241 | Received 12 Jul 2016, Accepted 14 Oct 2016, Published online: 03 Nov 2016

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Kengo Tokunaga, Chihiro Suzuki, Miyuki Hasegawa & Ikuo Fujimori. (2021) Cost Analysis in Helicobacter pylori Eradication Therapy Based on a Database of Health Insurance Claims in Japan. ClinicoEconomics and Outcomes Research 13, pages 241-250.
Read now

Articles from other publishers (18)

K. ANUSHA & G. SOWJANYA. (2024) A RELIABLE RP-UPLC-TUV METHOD FOR SIMULTANEOUS ESTIMATION OF CLARITHROMYCIN, AMOXICILLIN, AND VONOPRAZAN IN CO-PACKED PHARMACEUTICAL DOSAGE FORMS: METHOD DEVELOPMENT AND VALIDATION WITH STABILITY INDICATING PROPERTIES. International Journal of Applied Pharmaceutics, pages 351-357.
Crossref
Gocha Chankseliani, Avtandil Girdaladze, Omar Gibradze, Paata Meshveliani, Kakha Chelidze, Mirian Cheishvili, Ana Kvernadze & Nodar Sulashvili. (2023) THE FEATURES OF ENDOVASCULAR SURGERY FOR DUODENAL ULCER BLEEDING. World Science:4(82).
Crossref
Yuichiro Noiri & Ryoko Nagata. (2023) Current status of gastric and oral infection/diseases caused by Helicobacter pylori . Oral Science International 20:3, pages 182-189.
Crossref
Ismaeel Yunusa & Bryan L. Love. (2023) Cost-Effectiveness of Vonoprazan-Based and Rifabutin-Based vs Other Regimens as First-Line Treatment of Helicobacter pylori Infection in the United States. American Journal of Gastroenterology 118:4, pages 635-644.
Crossref
Colin W. Howden, Erin E. Cook, Elyse Swallow, Karen Yang, Helen Guo, Corey Pelletier, Rinu Jacob & Kentaro Sugano. (2023) Real-world outcomes associated with vonoprazan-based versus proton pump inhibitor-based therapy for Helicobacter pylori infection in Japan . Therapeutic Advances in Gastroenterology 16, pages 175628482311687.
Crossref
G. V. Osyodlo, O. V. Tsyts, S. M. Prokopchuk, Y. Y. Kotyk & V. V. Osyodlo. (2022) Ерозивно-виразкові захворювання гастродуоденальної зони у військовослужбовців: клінічні та фармакоекономічні аспекти. Ukrainian Journal of Military Medicine 3:1, pages 51-59.
Crossref
Chalermrat Bunchorntavakul & Arunluk Buranathawornsom. (2021) Randomized clinical trial: 7‐day vonoprazan‐based versus 14‐day omeprazole‐based triple therapy for Helicobacter pylori . Journal of Gastroenterology and Hepatology 36:12, pages 3308-3313.
Crossref
Soichiro Sue & Shin Maeda. (2021) Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Helicobacter pylori Eradication? . Gut and Liver 15:6, pages 799-810.
Crossref
Muhammad Miftahussurur, Boby Pratama Putra & Yoshio Yamaoka. (2020) The Potential Benefits of Vonoprazan as Helicobacter pylori Infection Therapy. Pharmaceuticals 13:10, pages 276.
Crossref
Mitsushige Sugimoto, Daiki Hira, Masaki Murata, Takashi Kawai & Tomohiro Terada. (2020) Effect of Antibiotic Susceptibility and CYP3A4/5 and CYP2C19 Genotype on the Outcome of Vonoprazan-Containing Helicobacter pylori Eradication Therapy. Antibiotics 9:10, pages 645.
Crossref
Shu Kiyotoki, Jun Nishikawa & Isao Sakaida. (2020) Efficacy of Vonoprazan for <i>Helicobacter pylori</i> Eradication. Internal Medicine 59:2, pages 153-161.
Crossref
Mitsushige Sugimoto & Yoshio Yamaoka. (2019) Role of Vonoprazan in Helicobacter pylori Eradication Therapy in Japan. Frontiers in Pharmacology 9.
Crossref
Haruhiko Ozaki, Satoshi Harada, Toshihisa Takeuchi, Shinpei Kawaguchi, Yoshiaki Takahashi, Yuichi  Kojima, Kazuhiro Ota, Yasushi Hongo, Kiyoshi Ashida, Masahiro Sakaguchi, Satoshi Tokioka, Hiroki Sakamoto, Takahisa Furuta, Kazunari Tominaga & Kazuhide Higuchi. (2018) Vonoprazan, a Novel Potassium-Competitive Acid Blocker, Should Be Used for the Helicobacter pylori Eradication Therapy as First Choice: A Large Sample Study of Vonoprazan in Real World Compared with Our Randomized Control Trial Using Second-Generation Proton Pump Inhibitors for Helicobacter pylori Eradication Therapy. Digestion 97:3, pages 212-218.
Crossref
Shou Quan Dong, Tikka Prabhjot Singh, Xin Wei, Huang Yao & Hong Ling Wang. (2017) Review: A Japanese population‐based meta‐analysis of vonoprazan versus PPI for Helicobacter pylori eradication therapy: Is superiority an illusion? . Helicobacter 22:6.
Crossref
Anthony O'Connor, Dominique Lamarque, Javier P. Gisbert & Colm O'Morain. (2017) Treatment of Helicobacter pylori infection 2017 . Helicobacter 22:S1.
Crossref
Y. S. Jung, E. H. Kim & C. H. Park. (2017) Systematic review with meta‐analysis: the efficacy of vonoprazan‐based triple therapy on Helicobacter pylori eradication . Alimentary Pharmacology & Therapeutics 46:2, pages 106-114.
Crossref
. (2017) Amoxicillin/clarithromycin/vonoprazan. Reactions Weekly 1649:1, pages 27-27.
Crossref
Mika Miura, Masahiko Ohtaka, Mitsuhiko Hanawa, Naoki Shimura, Yoshioki Yoda & Sho Suzuki. (2017) Gastric Mucosal Atrophy Might Be Associated with the Efficacy of First-Line Therapy Using Vonoprazan for <i>Helicobacter pylori</i>. Open Journal of Gastroenterology 07:09, pages 243-259.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.